

HR 3199

Term Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Commerce

Introduced: Jun 11, 2019

Current Status: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Latest Action: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet. (Jun 28, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/3199>

Sponsor

Name: Rep. Jeffries, Hakeem S. [D-NY-8]

Party: Democratic • **State:** NY • **Chamber:** House

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cline, Ben [R-VA-6]	R · VA		Jun 11, 2019
Rep. Collins, Doug [R-GA-9]	R · GA		Jun 11, 2019
Rep. Mucarsel-Powell, Debbie [D-FL-26]	D · FL		Jun 11, 2019
Rep. Roy, Chip [R-TX-21]	R · TX		Jul 30, 2019
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Sep 19, 2019

Committee Activity

Committee	Chamber	Activity	Date
Judiciary Committee	House	Referred to	Jun 28, 2019

Subjects & Policy Tags

Policy Area:

Commerce

Related Bills

No related bills are listed.

Terminating the Extension of Rights Misappropriated Act of 2019 or the Term Act of 2019

This bill addresses double patenting with respect to drug-related patents. Specifically, the bill requires an owner of drug-related patents, if the owner lists more than one patent as covering a particular drug, to prove in certain proceedings that each patent covers a distinct invention. If the patent owner fails to do so, then the owner shall have disclaimed patent protection from all the listed patents after the first patent expires.

This requirement shall apply to various proceedings challenging the validity of drug-related patents, as well as to infringement lawsuits filed by the patent owner against companies seeking Food and Drug Administration approval for generic or biosimilar versions of patented drugs.

The bill also directs the U.S. Patent and Trademark Office (USPTO) to review its examination procedures to prevent granting multiple patents for the same drug or biological product, unless the patents cover distinct inventions. The USPTO shall report to Congress its findings and recommendations from the review.

Actions Timeline

- **Jun 28, 2019:** Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
- **Jun 11, 2019:** Introduced in House
- **Jun 11, 2019:** Referred to the House Committee on the Judiciary.